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Abstract
L-DOPA decarboxylase (DDC) plays an essential role in the enzymatic synthesis of dopamine and alterations in its gene
expression have been reported in several malignancies. Our objective was to analyze DDC messenger RNA (mRNA)
and protein expression in laryngeal tissues and to evaluate the clinical implication of this molecule in laryngeal cancer.
In this study, total RNA was isolated from 157 tissue samples surgically removed from 100 laryngeal cancer patients.
A highly sensitive real-time polymerase chain reaction methodology based on SYBR Green I fluorescent dye was de-
veloped for the quantification ofDDCmRNA levels. In addition, Western blot analysis was performed for the detection
of DDC protein. DDC mRNA expression was revealed to be significantly downregulated in primary laryngeal cancer
samples compared with their nonmalignant counterparts (P = .001). A significant negative association was also dis-
closed between DDC mRNA levels and TNM staging (P = .034). Univariate analysis showed that patients bearing
DDC-positive tumors had a significantly decreased risk of death (hazard ratio = 0.23, P = .012) and local recurrence
(hazard ratio = 0.32, P = .006), whereas DDC expression retained its favorable prognostic significance in the multi-
variate analysis. Kaplan-Meier curves further demonstrated that DDC-positive patients experienced longer overall and
disease-free survival periods (P = .006 and P = .004, respectively). Moreover, DDC protein was detected in both
neoplastic and noncancerous tissues. Therefore, our results suggest that DDC expression status could qualify as a
promising biomarker for the future clinical management of laryngeal cancer patients.
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Introduction
Laryngeal cancer, the most frequent type of head and neck malignancy,
accounts for approximately 2.2% of all cancer cases and 2.0% of all
cancer-related deaths in the European male population [1]. Approxi-
mately 95% of all laryngeal tumors are histologically categorized as
laryngeal squamous cell carcinomas (LSCCs), the development of
which is mainly linked to tobacco smoking and excessive alcohol con-
sumption, according to a plethora of epidemiological studies [2,3]. At
present, the prediction of survival of patients with LSCC and the sub-
sequent treatment selection rely on a number of tumor characteristics,
such as the TNM stage, the anatomic site of the tumor, and the pres-
ence of lymph node metastases. Of the previously mentioned clinico-
pathologic factors, the nodal status holds a prominent place in the
prognosis of this neoplasia because the presence of involved lymph
nodes decreases the long-term survival by 50% [2,4,5]. However, none
of these clinical parameters alone are adequate for accurately staging
patients in proper prognostic groups in order for them to receive the
most suitable treatment regimen.
During the last decade, the noteworthy progress in the translational
research area, through considerable advances in molecular biology
techniques and immunohistochemistry, in combination with the ex-
pansion of knowledge regarding the molecular networks underlying
the pathogenesis and the development of laryngeal cancer, has been
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the stimulus for characterizing novel biologic markers with potential
clinical applications in the diagnosis and the prognosis of the disease
[4,6,7]. The candidate indicators for LSCC investigated so far partici-
pate in a diverse range of physiological functions, including apoptosis,
cell cycle regulation, metabolism, immune response, and angiogenesis.
Unfortunately, none of these biomarkers have been incorporated into
the clinical management or treatment algorithms for laryngeal cancer
patients as it is essential to further evaluate their proposed diagnostic
and/or prognostic advantages [8,9]. Under these circumstances, it is of
utmost importance to identify new molecular agents that may serve as
diagnostic and/or prognostic markers to fuel up the effort against this
fatal malignancy.
L-DOPA decarboxylase (DDC, EC 4.1.1.28) is a pyridoxal-5′-
phosphate–dependent enzyme participating in the biosynthesis of
catecholamines, a major class of neurotransmitters in the central ner-
vous system, with the principal role of catalyzing the decarboxylation
of L-3,4-dihydroxyphenylalanine (L-DOPA) to dopamine [10]. The
enzyme is composed of two homologous subunits, each of which
with a molecular weight of approximately 50 kDa and has been puri-
fied and characterized from human pheochromocytoma [11] and
kidney [12]. DDC presents a wide distribution in human tissues;
from the central nervous system, where it exerts its neurotransmitter
biosynthetic function, to a series of peripheral organs, such as the
liver, kidney, adrenals, lungs, gastrointestinal tract, and pancreas, in
which its biologic purpose is yet to be determined [10,13]. Although
it has been proposed that DDC may be implicated in the enzymatic
conversion of other aromatic amino acids in the extraneuronal tissues
[10], increasing evidence indicate that peripheral dopamine may be
involved in cell survival and proliferation [14].
The gene coding for DDC consists of 15 exons, covering more
than 85 kb of genomic DNA and is located to the chromosomal re-
gion 7p12.1-12.3 [15]. To date, a variety of different transcripts has
been described as the result of alternative splicing events, taking place
either in the 5′-untranslated or in the coding region of the DDC gene
[16–18]. Alterations in the messenger RNA (mRNA) expression pat-
terns of DDC have been associated with the diagnosis and prognosis
of various human malignancies. Although DDC expression status
is considered a well-established marker for neuroendocrine tumors
[19,20], its clinical usefulness has been recently proved in other solid
neoplasms as well [21,22].
To shed some light into the clinical significance of DDC expres-
sion and to evaluate its applicability as a prospective tissue biomarker
for enhancing the diagnostic and prognostic effectiveness in laryngeal
cancer, we analyzed the transcriptional activity of DDC in a set of
LSCC tissues and assessed its relationship with clinicopathologic fea-
tures and patient survival data by means of a highly specific and sen-
sitive real-time quantitative polymerase chain reaction (qPCR) assay.
Furthermore, to gain better insight about the protein product of DDC
gene, we performed immunoblot analysis experiments in cancerous
and normal laryngeal tissue extracts.
Materials and Methods
Laryngeal Cancer Patients and Tissue Specimens
For this retrospective study, 157 tissue samples were obtained
from 100 patients with histologically and clinically diagnosed LSCC,
who underwent surgical treatment for laryngeal cancer at Hippokra-
tion Hospital, Athens, Greece, during the period between 2005 and
2010. All resected tissue specimens, including 80 primary LSCC
samples, 20 recurrent LSCC specimens, and 57 paired surrounding
nonmalignant laryngeal tissues, were snap-frozen in liquid nitrogen
immediately after their surgical excision and stored at −80°C before
homogenization. None of the patients with primary LSCC received
preoperatively radiotherapy or chemotherapy, whereas most patients
who presented with local relapses were submitted to postsurgical
radiotherapy sessions.
Demographic data and clinical information of each patient of the
study cohort, such as age, sex, profession, tobacco and/or alcohol
consumption habits, follow-up period, and postoperative treatment,
were retrieved from the medical records of the hospital along with the
histopathologic characteristics of tumors (anatomic location, size,
TNM stage, and histologic grade). Of all the patients, 95% were
men with a mean age of 63.2 years at the time of the surgery (SE =
±0.92), ranging from 36 to 90 years. Approximately all patients had
been exposed to etiological factors of the disease such as tobacco smoke
and/or alcohol abuse. Among 99 patients, for whom complete follow-
up information concerning overall survival (OS) and disease-free sur-
vival (DFS) was available, 31 (31.3%) showed local recurrence and
18 (18.2%) died of LSCC. The follow-up period ranged from 4 to
60 months, with a median of 37 months for primary laryngeal cancer
patients and 36 months for those diagnosed with recurrent disease.
All scientific manipulations were conducted in agreement with the
ethical principles of the 1975 Declaration of Helsinki, as revised in
2000. In addition, the use of these clinical materials for research
purposes and the experimental protocols applied in this study were ap-
proved by the Hippokration Hospital of Athens Ethics Committee,
after notification of each patient participating in this study and acquisi-
tion of a signed informed consent form.
Cancer Cell Line and Culture Conditions
BT-474 is a cancer cell line of epithelial origin (number HTB-20;
ATCC, Wesel, Germany), initially isolated from invasive breast ductal
carcinoma. BT-474 cells were plated and cultured in RPMI 1640
growth medium (PAA, Pasching, Austria) supplemented with 10%
fetal bovine serum, 100 U/ml penicillin, 100 μg/ml streptomycin,
0.3 g/ml L-glutamine, 0.85 g/L NaHCO3, and 10 μg/ml insulin at
37°C in a humidified atmosphere supplied with 5% (vol/vol) CO2.
Total RNA Isolation and Reverse Transcription
Total RNA was extracted from 10 to 100 mg of snap-frozen LSCC
or tumor-adjacent normal tissue fragments, as well as from BT-474
cells, using TRI Reagent (Ambion, Austin, TX) in accordance with the
manufacturer’s protocol. The isolated RNA was preserved in RNA
Storage solution (Ambion) and stored at −80°C. The concentration of
the RNA solution was determined spectrophotometrically by measuring
the absorbance at 260 nm and its purity was estimated on the basis
of the absorbance ratio at 260 and 280 nm. Moreover, the integrity of
the extracted RNA was evaluated by electrophoresis on 1.5% agarose
gel stained with ethidium bromide.
From 1 μg of total cellular or laryngeal tissue RNA, 20 μl of first-
strand complementary DNA (cDNA) was synthesized with the use of
Oligo-dT primers and the M-MuLV Reverse Transcriptase RNase H−
(Finnzymes, Vantaa, Finland), combined with the Human Placen-
tal RNase Inhibitor (H T Biotechnology Ltd, Cambridge, United
Kingdom). The resulting cDNA was used for subsequent real-time
qPCR experiments.
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Quantitative Real-time PCR
Quantification of DDC mRNA expression levels in the laryngeal
tissue samples was achieved with the development of a real-time PCR
methodology of exceptional sensitivity and reliability, based on the SYBR
Green I fluorescent dye detection chemistry (Applied Biosystems, Foster
City, CA). Two pairs of gene-specific oligonucleotide primers were de-
signed and synthesized on the basis of the reference mRNA sequences
published on the NCBI database, one set for the gene of interest,
DDC (GenBank accession number NM_000790), and the other for
the internal control gene of the method, GAPDH (GenBank accession
number NM_002046). GAPDH, the gene that encodes glyceraldehyde-
3-phosphate dehydrogenase, was chosen as the reference gene because
of the stability of its expression and its overall suitability in the normaliza-
tion of quantitative expression data in the field of head and neck squa-
mous cell carcinoma [23]. The sequences of the two sets of primers
used are listed as follows: for GAPDH, the forward 5′-CCT CCC GCT
TCG CTC TCT-3′ and the reverse 5′-CCG TTG ACT CCG ACC
TTC AC-3′ primers produced an amplicon of 116 bp, whereas for
DDC, the forward 5′-GAA CAG ACT TAA CGG GAG CCT TT-3′
and the reverse 5′-AAT GCC GGT AGT CAG TGA TAA GC-3′ gave
rise to a 90 bp amplicon. The primers were designed to attach to
separate exons to avoid amplification of contaminating genomic DNA.
Real-time qPCR for both genes was performed in triplicate using an
ABI Prism 7500 thermal cycler (Applied Biosystems) for the whole set
of laryngeal tissue samples. The reaction mixture contained 0.4 μl of
cDNA, 50 nM of gene-specific primers and 2× Power SYBR Green
PCR MasterMix (Applied Biosystems) in a final reaction volume of
10 μl. Thermal cycling included an initial 10-minute step at 95°C
for the denaturation of the sample and the activation of AmpliTaq Gold
hot-start DNA polymerase, and the mixture was then subjected to
40 cycles of denaturation at 95°C for 15 seconds and primer annealing
and extension at 60°C for 1 minute. Following the amplification pro-
cess, a dissociation curve analysis was performed to confirm the speci-
ficity of the qPCR and to verify the presence of the desired amplified
sequences, by determining the characteristic melting temperature (Tm)
of each generated PCR amplimer (Figure 1, B and C).
The mRNA expression of DDC for each laryngeal specimen was
calculated with the comparative C t method (2
−ΔΔC t), a relative quan-
tification method enabling us to estimate relative changes in the tran-
scriptional activity of the gene of interest [24], using the C t values
deduced from the real-time PCR fluorescent emission data and a cali-
brator, which in our experiments was the human breast tumor cell line
BT-474. Hence, the comparison of DDC expression, normalized to
GAPDH, between different laryngeal tissue samples in the study was
feasible by setting the calibrator’s normalized DDC expression as a
reference point. Our results were interpreted by introducing the arbi-
trary relative quantification (RQ) unit, calculated by the arithmetic
formula 2−ΔΔC t, where ΔΔC t equals to [(C t DDC − C t GAPDH)sample −
Figure 1. Quantitative determination of DDC expression in laryngeal tissue samples by qPCR. Amplification plots (A) for DDC and GAPDH
in a randomly selected laryngeal cancerous specimen, in which C t values for both genes, as well as ΔC t, are illustrated. Dissociation
curves of the GAPDH (B) and DDC (C) PCR products, in which a single peak at 84.3 and 80.4°C, respectively, corresponding to the desired
amplicon, is shown.
290 DDC Expression as a Marker for Laryngeal Cancer Patsis et al. Translational Oncology Vol. 5, No. 4, 2012
(C t DDC − C t GAPDH)calibrator] for every given sample. The RQ unit,
therefore, represents the normalized-to-GAPDH amounts of DDC
mRNA levels of a laryngeal tissue sample relative to the normalized
DDC expression of BT-474 cancer cells and provides a useful way to esti-
mate the relative changes in DDC expression between different samples.
Immunodetection of DDC Protein
A small subset of eight randomly selected samples, four LSCCs and
four matched nonneoplastic laryngeal tissues, whose DDC expression
at the mRNA level was recorded as positive in the qPCR experiments,
were further analyzed by Western blot. Total protein was extracted
from the laryngeal samples according to the TRI Reagent protein iso-
lation protocol (Ambion) and dissolved in 1% sodium dodecyl sulfate
(SDS). The total protein concentration of each sample was spectro-
photometrically determined at 595 nm, based on the Bradford protein
assay with bovine serum albumin as standard.
Protein samples (5 μg/lane) were separated at room temperature by
10% SDS–polyacrylamide gel electrophoresis (SDS-PAGE) on an
electrophoresis device (Cleaver Scientific, Rugby, United Kingdom) at
150V for 90minutes and then electrophoretically transferred onto a nitro-
cellulose membrane (Schleicher & Schuell Bioscience, Dassel, Germany)
using Trans-Blot SD semidry cell (Bio-Rad, Hemel Hempstead, United
Kingdom). After blocking overnight at 4°C in 1× TNT (10 mM Tris,
150 mM NaCl, 0.05% Tween 20) with 10% bovine serum albumin,
DDC immunodetection was carried out using a polyclonal rabbit
primary antibody (diluted 1:1000) against 32 amino acids of the
C-terminal region of human DDC, raised from our laboratory. The
membranes were subsequently submitted to chromogenic staining with
an alkaline phosphatase–conjugated goat anti-rabbit secondary antibody
(diluted 1:20,000; Chemicon International, Temecula, CA), leading to
the development of a characteristic band that corresponds to DDC.
Statistical Analysis
The nonparametric Wilcoxon signed ranks test was used for the
analysis of the differences in DDC expression patterns between neo-
plastic and noncancerous laryngeal samples because the expression
levels of DDC in these groups did not display a normal distribution.
By using the X-tile algorithm, an optimal cutoff point for DDC was
generated, equal to 0.06 RQ units, to classify DDC mRNA expres-
sion of each sample as positive or negative, depending on whether the
RQ units were above or below this cutoff point. Relationships between
DDC expression status and the clinicopathologic variables and pa-
tients’ age were also examined by implementing the χ2 test or Fisher
exact test, where appropriate. The diagnostic assistance of DDC ex-
pression profiles was assessed by constructing receiver operating char-
acteristic (ROC) curves, depicting the sensitivity versus (1 − specificity)
for all possible cutoff values. The areas under the curves (AUCs) were
analyzed using the method of Hanley and McNeil. Univariate and
multivariate analyses were carried out using Cox proportional hazards
models. Survival curves for OS and DFS were designed with the
Kaplan-Meier method and compared using the log-rank test. The
significance level was set at P < .05.
Results
Validation of DDC mRNA Relative Quantification in
Laryngeal Tissues with qPCR
The quantitative determination of DDC mRNA expression in the
complete collection of laryngeal tissue specimens was accomplished
by selecting a relative quantification approach, the comparative C t
method (2−ΔΔC t), with the intention of analyzing the acquired data
from the two-step reverse transcription real-time PCR methodology
implemented in this study. The comparative C t method (2
−ΔΔC t),
the principle of which requires a reference gene and a calibrator sam-
ple, takes advantage of the C t values generated from the amplification
plots of GAPDH and DDC (Figure 1A).
The basic assumption, however, to apply this relative quantification
method, is that the amplification efficiencies of both target and refer-
ence genes must be approximately equal and, if possible, to exceed
90% [24]. Serially diluted samples of BT-474 cDNA, derived from
200 to 0.01 ng of total RNA, were subjected to amplification for both
genes in an attempt to confirm the above hypothesis. The qPCR ef-
ficiencies were calculated from the slope of the standard curves created
by plotting the C t values against the logarithm of the input RNA
mass (Figure 2). Conducting this experiment, comparable efficiencies
for both GAPDH (3.5244, 92.2% efficiency, R2 = 0.9939) and DDC
(3.3745, 97.8% efficiency, R2 = 0.9951) were demonstrated, thus
rendering the 2−ΔΔC t method acceptable for the quantitative evaluation
of DDC transcriptional levels.
Analysis of DDC Expression in Laryngeal Tissues
The distribution of DDC mRNA expression pattern in patients
with laryngeal cancer is displayed in Table 1. Detectable DDC tran-
script levels were observed in both cancerous and tumor-adjacent
Figure 2. Validation of the 2−ΔΔC t method by constructing standard
curves for both DDC and GAPDH using as template serial dilutions
of BT-474 cDNA.
Table 1. Descriptive Statistics of DDC Expression in Laryngeal Tumor Samples.
DDC Expression (RQ Units) Mean ± SE* Range Quartiles
Lower Median Upper
Noncancerous tissues (n = 57) 98.1 ± 31.4 0.03-1196.8 4.8 21.8 52.5
Primary cancerous tissues (n = 80) 28.7 ± 9.0 0.03-552.6 0.06 1.8 16.2
Recurrent cancerous tissues (n = 20) 32.9 ± 16.7 0.03-269.8 0.03 1.6 9.4
*SE indicates standard error.
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nonmalignant laryngeal tissues. Nevertheless, the expression analysis of
DDC at the mRNA level showed a three-fold decrease in both primary
(mean ± SE = 28.7 ± 9.0 RQ units) and recurrent (mean ± SE =
32.9 ± 16.7 RQ units) laryngeal carcinomas in comparison with
the nonneoplastic laryngeal mucosa samples (mean ± SE = 98.1 ±
31.4 RQ units). No differentiation regarding DDC expression is
noticed between primary and relapsed LSCCs. When the laryngeal
specimens were examined as pairs of cancerous and matched non-
cancerous tissues, a statistically significant down-regulation of the
DDC transcriptional activity (P = .001) was revealed only in the case
of primary LSCCs, where approximately 78% of the patients demon-
strated higher DDC mRNA levels in the surrounding nonmalignant
tissue samples compared to their tumor counterparts (Table 2).
The expression of DDC protein was screened in eight randomly
selected laryngeal samples by Western blot analysis, using a human
kidney cancer sample as a positive control. The immunoblot analysis
experiment uncovered the existence of a singe-specific band for DDC
at the anticipated molecular mass in both LSCC and tumor-free tis-
sue specimens (Figure 3). In addition, it is clearly denoted that DDC
protein is differentially expressed between the malignant and non-
malignant laryngeal samples analyzed, with the noncancerous ones
to be characterized by greater DDC protein production. However,
the DDC protein levels of these laryngeal tissues are consistent with
their respective mRNA levels, as determined with real-time PCR.
Assessment of the Diagnostic Ability of DDC Expression Status
in Laryngeal Cancer
ROC curve analysis was used to explore the discriminatory potential
of DDC transcription levels between cancer of the larynx, of primary
origin or recurrence, and the nonpathologic state (Figure 4). The ex-
ported ROC curves indicated the significant diagnostic value of DDC
expression levels in LSCC (AUC = 0.71, 95% confidence interval =
0.63-0.81, P < .001 for primary tumors; and AUC = 0.73, 95% con-
fidence interval = 0.59-0.87, P = .002 for recurrent ones) and support
its role as a diagnostic classifier in laryngeal cancer.
Association of DDC Expression with Clinicopathologic
Variables in Primary LSCC
In the next step of the study, we evaluated the possible correlations
between DDC mRNA expression profile and a series of clinical and
histopathologic parameters concerning laryngeal cancer patients with
Table 2. DDC Expression in Pairs of Cancerous and Noncancerous Laryngeal Tissue Specimens.
DDC Expression in Pairs No. Patients (%) P*
Primary tumors
Higher in noncancerous vs cancerous samples 35 (77.8) .001
Lower in noncancerous vs cancerous samples 7 (15.6)
Equal in noncancerous and cancerous samples 3 (6.6)
Recurrent tumors
Higher in noncancerous vs cancerous samples 7 (63.6) .37
Lower in noncancerous vs cancerous samples 4 (36.4)
*Calculated using the nonparametric Wilcoxon signed ranks test.
Figure 3. Immunologic detection of DDC in representative LSCCs and nonmalignant laryngeal tissues by using anti-DDC polyclonal
antibody. Lanes refer to the following: 1, molecular weight marker; 2, positive control (human kidney cancer); 3, 5, 7, 9, nonmalignant
laryngeal samples; 4, 6, 8, 10, tumor specimens.
Figure 4. ROC curve analysis for DDC mRNA expression in laryn-
geal tissues demonstrating its potential role in the diagnosis of pri-
mary (A) or recurrent (B) LSCC.
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primary tumors, as synopsized in Table 3. Consistent with our re-
sults, a statistically significant inverse association (P = .034) was dis-
covered between DDC expression status and the TNM stage of the
disease. In particular, the frequency of DDC positivity was signifi-
cantly lower in tumors of advanced TNM stage (II-IV), as opposed
to those of stage I. However, no statistically significant relationships
were established between DDC expression pattern and histologic grade
(P = .99) or patients’ age (P = .44).
Prognostic Implications of DDC mRNA Expression in
Primary Laryngeal Cancer
The predictive strength of DDC transcriptional status concerning
the clinical course of patients coping with laryngeal cancer was specified
by developing univariate and multivariate Cox proportional hazards
regression models (Table 4). As disclosed by the univariate analysis,
DDC expression, at the mRNA level, presented a statistically significant
association with both OS (P = .012) and DFS (P = .006), given that
patients with DDC-positive laryngeal carcinomas showed a decreased
risk of death (hazard ratio [HR] = 0.23) or relapse (HR = 0.32). More
than that, when other clinicopathologic variables were introduced in
the multivariate analysis, the prognostication power of DDC mRNA
profile remained, implying that DDC expression may serve as an in-
dependent favorable prognostic indicator for both OS (P = .008) and
DFS (P = .002). As expected, Kaplan-Meier survival curves (Figure 5)
also illustrated that patients harboring DDC-positive primary laryngeal
tumors exhibited a significantly longer OS and DFS (P = .006 and P =
.004, respectively), compared to those whose neoplasms were classified
as DDC-negative.
Discussion
Cancer of the larynx constitutes the most prevalent form of head and
neck malignancy in the Mediterranean basin, especially in Greece,
where it is estimated to be responsible for more than 50% of these
occurrences [25,26]. A recent meta-analysis, based on a series of pub-
lished studies, revealed that the overall 5-year relative survival rate of
laryngeal cancer patients was approximately 64%, one of the lowest
comparing with other types of cancer [27], regardless of the latest
advances in surgical procedures, combined treatment modalities
and chemotherapeutic protocols that have been documented the past
two decades [28]. Among the reasons behind this adverse prognosis
of patients with LSCC is the clinically silent nature of this neoplasia
at the time of presentation, the insufficiency of the TNM staging
system to accurately stratify patients into more consistent prognostic
groups, and the pronounced biologic heterogeneity of this disease, in
which diverse molecular and genetic abnormalities are masked under
seemingly identical phenotypes [8,28]. The major challenge, there-
fore, in laryngeal cancer is to escalate research efforts by focusing
on the identification and development of new molecular-based
tumor markers that could empower the clinical management and
eventually expand the life span of patients with LSCC.
In the last few years, accumulated evidence has shown that dopa-
mine, as well as other biogenic amines, participates in a wide range of
biochemical pathways in the nonneuronal tissues, which directly
relate to cancer progression [14]. One such physiological process,
in which dopamine has been reported to mediate, is the formation
of new blood vessels. It is now generally acknowledged that dopa-
mine is an endogenous inhibitor of tumor angiogenesis, suppressing
in this way the growth and proliferation of malignant tumors [29].
Another example of the antiproliferative effects of dopamine lies in
gastric cancer, where it was recently demonstrated that dopamine
negatively regulates tumor cell proliferation through specific molec-
ular interactions resulting in cell cycle arrest [30]. Moreover, dopa-
mine was also found to stimulate apoptosis in one leukemia and
several oral squamous cell carcinoma cell lines [31,32]. Taking all
the above into consideration, we investigated, in this research work,
both the mRNA and protein expression of DDC, the enzyme re-
sponsible for the enzymatic conversion of L-DOPA to dopamine,
in laryngeal tissue samples with the aim of elucidating its clinical
utilization as a molecular biomarker for LSCC.
As far as we know, this is the first time the transcriptional and
translational expression of DDC is being examined in laryngeal tis-
sues. Apart from its existence in all aminergic cells of the central and
peripheral neurotransmitter systems, DDC has also been detected in
peripheral organs including liver, kidney, and pancreas [10]. Further-
more, Kokkinou et al. [33] have recently reported that enzymatically
active DDC is localized in human peripheral leukocytes, thus expand-
ing the already-accepted distribution pattern of this catecholamine
biosynthetic enzyme.
Our study revealed detectable levels of DDC mRNA in all laryngeal
tissue groups. However, a statistically significant underexpression of the
gene (P = .001) in the primary LSCC tissue specimens was observed,
when compared to the neighboring nonmalignant laryngeal samples.
This discernible down-regulation of DDC in laryngeal cancer could
Table 3. Correlation between DDC Expression Status and Certain Clinicopathologic Features in
Patients with Primary Laryngeal Cancer.
Variable Total No. Patients No. Patients (%) P
DDC-Negative* DDC-Positive*
TNM stage
I 13 0 (0.0) 13 (100.0) .034†
II-IV 67 18 (26.9) 49 (73.1)
Grade
1/2 44 10 (22.7) 34 (77.3) .99†
3 32 7 (21.9) 25 (78.1)
x 4
Age (years)
<55 12 1 (8.3) 11 (91.7) .44‡
55-65 36 9 (25.0) 27 (75.0)
>65 32 8 (25.0) 24 (75.0)
x indicates unknown.
*Cutoff point = 0.06 RQ units (23rd percentile).
†Calculated with the Fisher exact test.
‡Calculated with the χ2 test.
Table 4. Univariate and Multivariate Analyses of DDC Expression Levels regarding DFS and OS
of Patients with Primary Laryngeal Cancer.
DFS OS
HR* 95% CI† P‡ HR* 95% CI† P‡
Univariate analysis
DDC-negative 1.00 1.00
DDC-positive 0.32 0.14-0.73 .006 0.23 0.076-0.73 .012
Multivariate analysis§
DDC-negative 1.00 1.00
DDC-positive 0.23 0.09-0.57 .002 0.18 0.05-0.64 .008
*Hazard ratios (HRs) were estimated from the Cox proportional hazard regression model.
†Confidence interval of the estimated HR.
‡Test for trend.
§Multivariate models were adjusted for patients’ age, tumor grade, and smoking and alcohol
consumption.
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be possibly attributed to the general deregulation of the cell’s transcrip-
tion mechanism to which it is subjected during the malignant transfor-
mation. The diagnostic utility of this particular finding in laryngeal
cancer was highlighted by the ROC curve analysis, according to which
theDDCmRNA expression profile could assist the diagnosis of LSCC,
primary (AUC = 0.71, P < .001) or recurrent (AUC = 0.73, P = .002),
by discriminating the noncancerous condition from the neoplastic dis-
ease. Previous studies have already proposedDDC transcriptional status
as a propitious marker for the diagnosis of various malignancies. Spe-
cifically, Gilbert et al. [34] suggested that the levels of DDC expression
could be exploited for the accurate differential diagnosis of neuro-
blastoma from other pediatric small round cell neoplasms, whereas it
was also recommended as an indicator for detecting neuroblastoma
cells in the bloodstream or the bone marrow with great specificity
[19]. Similarly, the experiments by Avgeris et al. [21] supported the
notion that DDC transcriptional modulations could be useful for dis-
tinguishing between prostate cancer and benign prostate hyperplasia.
Consequently, we could safely assume that the fluctuations of DDC
transcriptional activity in laryngeal cancer might contribute to the early
diagnosis of this, often asymptomatic at the early stages, malignancy
and the detection of minimal residual disease at the margins of the
surgical resection, which is associated with increased risk of local
recurrence and death.
Another interesting finding of our present research was the revelation
of a statistically significant negative correlation between the mRNA
expression ofDDC and the TNM classification of the primary laryngeal
tumors (P = .034). Of note, all stage I laryngeal carcinomas wereDDC-
positive, in contrast with the laryngeal tumors of advanced clinical stage
(II-IV), from which a percentage of 73.1% exhibited expression levels
above the calculated cutoff for DDC. Because early-stage laryngeal
malignancies tend to present higher cure rates and usually the patients’
life span could be prolonged, elevated DDC expression levels could
comprise a molecular indicator of favorable prognosis for patients with
LSCC. However, this is not the sole survey unveiling a fundamental
relationship between DDC mRNA expression and the progression of
different types of cancer. In the case of colorectal adenocarcinoma,
the expression status of DDC was found to be significantly associated
with the histologic grade of the tumors examined [22], whereas in
patients with gastric cancer, DDC transcriptional status correlated with
various features characterizing the natural course of this neoplasia,
such as differentiation, depth of invasion, lymphatic invasion, and peri-
toneal dissemination [35]. Likewise, from a research work conducted
in prostate cancer, a possible connection between DDC mRNA levels
and the pathologic stage of this malignancy was emerged, implying
the role of this enzyme in the development and progression of this
neoplasia [36].
Along this line lies the fact that patients bearing DDC-positive
primary laryngeal tumors live considerably longer (P = .006) and with-
out disease relapses (P = .004) than those with LSCCs negative for
DDC expression, as depicted on the Kaplan-Meier graphs. As esti-
mated by the survival analysis, the 5-year OS for DDC-positive pa-
tients was 90% contrary to the approximately 62% for patients with
DDC-negative laryngeal cancer. Comparable results were obtained
from Cox univariate regression analysis, which clearly showed that pa-
tients coping with DDC-negative laryngeal neoplasms had about three
times higher risk of experiencing locoregional recurrence (P = .006,
HR = 0.32) and about four times greater probability of succumbing
to the disease (P = .012, HR = 0.23). On top of that, the multivariate
analysis stressed out the independent prognostic significance of DDC
mRNA expression status as a favorable predictive marker for both OS
(P = .008) and DFS (P = .002) of patients with primary LSCC. As
an immediate consequence, DDC expression may act as a substantial
and reliable indicator, alone or as component of a broader clinico-
molecular multiparametric panel, for designating patients with LSCC
into rigorous risk groups, so as to facilitate the selection of the appro-
priate candidates, who would benefit from more aggressive treatment
approaches. Analogous observations were made by Kontos et al. [22]
in colorectal adenocarcinoma, where it was described that the reduction
in DDC mRNA amounts adversely influenced the clinical outcome of
patients, pertaining not only the DFS but also the OS. Particularly, it
was shown that patients with DDC-positive adenocarcinomas pre-
sented approximately five times higher survival probability, as well as
Figure 5. Kaplan-Meier survival curves for the DFS (A) and OS (B) of patients with primary laryngeal tumors categorized as either
DDC-positive or DDC-negative.
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about four times lower risk of recurrence. We could surmise that the
prognostic impact of enhanced DDC transcriptional activity in the
survival of LSCC patients might be associated with the accompanied
increment in the production of dopamine, which, as mentioned before,
has proved to possess distinct tumor-protective effects in numerous
reports [14].
Adding to the clinical importance of DDC gene in laryngeal cancer,
we concentrated our attention on the detection of its protein product
in the laryngeal samples. According to Western blot analysis, a unique
band representing DDC was successfully detected in both malignant
and noncancerous laryngeal protein extracts, indicating that the
DDC enzyme is normally expressed not only in the human larynx,
perhaps as an integral part of the laryngeal physiology, but also in
the neoplastic conditions of this organ. Recently, a study performed
byGoulioumis et al. [37] suggested a critical role for androgen receptors
(ARs) in the pathobiology of squamous laryngeal cancer, based on
their immunohistochemical data regarding the expression of ARs in this
neoplasia. Other authors evidenced that DDC interacts with AR at the
cytoplasmic level, escalating its transcriptional activity, which, in turn,
differentially modifies the expression patterns of AR-regulated genes in
prostate cancer cells [38,39]. Hence, a reasonable speculation, arising
from these surveys, is that DDC is implicated in the development
and progression of laryngeal cancer through its ability to indirectly
alter the mRNA levels of genes that are under the transcriptional
control of ARs.
In conclusion, this is the first report in the literature that provides
compelling evidence about the transcriptional and translational status
of DDC in laryngeal tissues and eventually confirms the paramount
diagnostic and prognostic opportunities emerging from the quantifica-
tion of DDC mRNA expression levels in LSCC. Although future stud-
ies are indispensable to evaluate and integrate these findings into clinical
decision making, the present research strongly signifies DDC as a
promising molecular tumor marker for this head and neck malignancy.
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